Emmecell has secured a strategic financing round, with Bausch + Lomb participating, to further its clinical programs and magnetic cell delivery platform. The specific amount of this undisclosed round was not revealed, but it marks a significant step in advancing their therapeutic development. Funds will be directed towards accelerating clinical trials and enhancing their proprietary technology.
